Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial.
Peng Z, Li H, Gao Y, Sun L, Jiang J, Xia B, Huang Y, Zhang Y, Xia Y, Zhang Y, Shen Y, Huang B, Nie J, Chen X, Liu X, Feng C, Li Z, Zhang W, Tao K, Zhang Q, Duan S, Chen Y, Chen Y, Wang W, Zheng H, Lu Y, Liu Y, Wang L, Qi W, He Y, Tian Y; NUWA Platform Research Group; Li G, Ma D, Gao Q.
Peng Z, et al.
Lancet Oncol. 2024 Oct;25(10):1288-1297. doi: 10.1016/S1470-2045(24)00437-6. Epub 2024 Sep 11.
Lancet Oncol. 2024.
PMID: 39276785
Clinical Trial.